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Summary Seven hundred and eighty-six subjects spontaneously referring to our Center performed two guaiac
(Rehydrated Hemoccult II (R.HO), and Hemoccult Sensa (HO S.)), and two immunochemical (OC Hemodia
(Hdia) and Hemeselect (Hsel)) faecal occult blood tests on three consecutive faecal determinations. The
positivity rates of 3 day RHO, HO S., Hdia, and Hsel were 4.8%, 5.6%, 8.4% and 11.2% respectively. One
hundred and thirty-five of the 150 subjects with at least one positive test completed the diagnostic work-up.
Cancer was detected in three subjects and adenomas in 15.
Three-day specificity estimates of RHO, HO S., Hdia and Hsel in the overall series were 96.1%, 96.0%,
93.8% and 91.2% respectively, the differences between guaiac and immunochemical tests being significant.
Corresponding values of specificity as determined on the first faecal sample only in the overall series were
98.1%, 98.3%, 96.1% and 94.9% respectively.
No significant difference in specificity is evident when 3-day guaiac tests are compared to 1-day
immunochemical ones.
Three-day immunochemical testing is not recommended for screening purposes due to its very low
specificity.
Nevertheless, 1-day immunochemical testing is almost as specific as 3-day guaiac testing. A preliminary
estimate of colonic neoplasms detection rates shows no difference as well.
The benefit of 1-day testing on screening acceptability is evident, but the impact on sensitivity should be
evaluated in a screening situation with a proper study design and a larger sample size.
Screening by means of faecal occult blood testing (F.O.B.T.)
has been proposed to reduce the incidence of and the mortal-
ity from colorectal cancer.
The Hemoccult test, based on guaiac impregnated slides, is
the most frequently used test both in field programs and in
randomised trials. Unfortunately, evidence of screening
efficacy is still lacking, although some controlled trials have
been ongoing for many years (Hardcastle et al., 1989; Kron-
borg et al., 1989; Mandel et al., 1988).
The low sensitivity of the Hemoccult test, ranging between
50 and 70% in the majority of the ongoing cases (Hardcastle
et al., 1989; Kronborg et al., 1989; Bertario et al., 1988;
Castiglione et al., 1991) is one of the major problems in
colorectal cancer screening.
The specificity of the Hemoccult in population-based
screenings is about 98%; false-positive results may be ascr-
ibed to non-neoplastic bleeding, non-human haemoglobin
and the peroxidase-like activity of some vegetables and fruits,
thus requiring a restrictive diet (Macrae et al., 1982).
Rehydration of Hemoccult slides increases the sensitivity
up to 85-90%, but specificity is reduced to approximately
95% (Kewenter et al., 1988).
In recent years, new tests have been introduced. Some of
them are based on an immunochemical reaction specific for
human haemoglobin. Neither the sensitivity nor the spec-
ificity of these tests have been exhaustively studied in a
screening setting although some preliminary reports suggest a
higher sensitivity of immunochemical tests as compared to
guaiac ones (St John et al., 1989; Shimizu et al., 1987).
The aim of our study is to compare specificity and predic-
tivity for cancer and adenomas of four F.O.B.T. methods,
for both 1-day and 3-day testing, in order to assess their
possible role as screening test. The tests used were: Hem-
occult II (SK&D) developed after rehydration, Hemoccult
Sensa (SK&D, a guaiac test with an enhanced hydrogen
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peroxide concentration in the developer), OC-Hemodia
(Eiken, latex agglutination test) and Hemeselect (SK&D,
reverse haemagglutination test).
Material and methods
All subjects spontaneously referring to our Center for early
detection of colorectal cancer were invited to perform the
four tests for three consecutive bowel movements using the
kits provided by the manufacturers.
Patients were advised not to eat red meat for 2 days before
and during faeces sample collection. Patients were also
recommended to sequentially collect faecal samples in kits
numbered from one to three for each test. Returned tests
were developed in our laboratory according to manufac-
turer's recommendations. Hemoccult II was developed after
rehydration of specimens.
FOBT-negative subjects were invited to repeat screening
after 2 years. Patients were also advised to visit their
physicians to manage any complaint occurring either before
the time of screening or in the interval.
Subjects with at least one positive test were invited to
undergo pancolonoscopy or a combination of left colon-
oscopy and double contrast barium enema when pancolonos-
copy was not possible.
From January 1990 up to July 1991, 786 patients were
consecutively accrued in the study (350 males, 436 females)
excluding those subjects not completing the four tests for 3
days. Mean age was 55.8 years (males 56.2, females 55.5).
Six hundred and thirty subjects were fully asymptomatic as
recorded by an anamnestic questionnaire completed by each
patient at referral; 156 subjects were affected by rectal
bleeding, and/or alterations in bowel habits and/or ab-
dominal pain.
Specificity and Positive Predictive Value (P.P.V.) of each
test for colorectal cancer and adenomas were determined
both on 3-day testing and 1-day testing, after exclusion of
those subjects who refused to complete the diagnostic work-
up. One-day testing was determined on the results of the first
bowel movement specimen only.
The differences between the specificity estimates of each
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test were checked by means of McNemar's test, significance
being set at P<0.05 (Rothman, 1986).
Results
The positivity rates on three consecutive samplings of
Rehydrated Hemoccult (R.HO), Hemoccult Sensa (HO S.),
OC Hemodia (Hdia) and Hemeselect (Hsel), calculated on
the whole series of 786 subjects, were 4.8% (n = 38; Asym-
ptomatic n = 21, Symptomatic n = 17), 5.6% (n = 44; Asy-
mptomatic n = 28, Symptomatic n = 16), 8.4% (n = 66;
Asymptomatic n = 46, Symptomatic n = 20), and 11.2%
(n = 88; Asymptomatic n = 63, Symptomatic n = 25) respec-
tively.
Overall 150 subjects had at least one positive test (at least
one positive determination).
Fifteen patients refused any endoscopic and radiologic
examination. One hundred and thirty-five underwent the
diagnostic phase.
Colorectal cancers were detected in three subjects and
single or multiple adenomas in 15 (Table I).
Three-day testing specificity rates and P.P.V.s for cancer
and adenomas were calculated for each test in 771 subjects
either negative on faecal occult blood testing or undergoing a
complete diagnostic work-up (asymptomatic = 619, sympto-
matic = 152) (Table II).
Immunochemical tests were less specific and less predictive
than guaiac tests in all subgroups considered. As regards
specificity, the differences between guaiac and immuno-
chemical tests are statistically significant with the only excep-
tion of HO S. as compared with Hdia in asymptomatic sub-
jects. No significant difference is evident between the two
guaiac tests, whereas Hdia is significantly more specific than
Hsel particularly in asymptomatic subjects. None of the
differences between tests is statistically significant in the
group of symptomatic subjects.
The positivity rates of 1-day testing of Rehydrated
Hemoccult (R.HO), Hemoccult Sensa (HO S), OC Hemodia
(Hdia) and Hemeselect (Hsel), were 2.4% (n = 19; Asympto-
matic n = 9, Symptomatic n = 10), 2.8% (n =22, Asymp-
tomatic n = 11, Symptomatic n = 11), 5.2% (n=41; Asymp-
Table I Neoplastic findings observed in 18 out of 135 subjects with at least one positive test for faecal occult
blood
Case Size
nr. Findings mm Histology R.HO HO.S HDIA HSEL
<asymptomatic subjects>
1 Cecal cancer Adenocarcinoma + + + + + + +++ + + +
2 Rectal cancer Adenocarcinoma + + + + + + +++ + + +
3 Transverse cancer Adenocarcinoma - - + - + - +++
4 Polyp 15 Tubularadenoma - + - + - - - - - -
5 Polyp 15 Tubulovillousad. - +- - + + + + +-
6 2 polyps 15 Tubular adenoma - - - - - - - - - - - -
7 Polyp 30 Tubular adenoma + + - + + + +++ + + +
8 Polyp 3 Tubular adenoma - - - + - + - - - - - -
9 Polyp 8 Tubulovillous ad. - -- +- + - - - - - -
10 Polyp 6 Tubular adenoma - -- - - - - - - - - -
11 4 polyps 15 Tubular adenoma - - - - - - - --. + -
12 Polyp 10 Tubular adenoma - + + - + + - + + + + +
13 Polyp 8 Tubularadenoma - - - - - - - - - - + +
<symptomatic subjects>
14 Polyp 7 Tubular adenoma -+ - + + - + -
15 2 polyps 10 Tubular adenoma - - - - -.- - -- + + +
16 11 polyps 40 Villous adenoma + + + + + + +++ + + +
17 2 polyps 7 Tubular adenoma + + - - - - - -
18 Polyp 15 Tubular adenoma - -- + - - - - - - . -
The results of each of three consecutive determinations are indicated for each test ( + = positive;
- = negative).
Table II Positivity rate, P.P.V. forcancerandadenomas, andspecificityestimates
at 3-day testing for each test according to symptomatic status
R.HO HO.S HDIA HSEL
Positivity All subjects 4.8% 5.6% 8.4% 11.2%
rates Asymptomatic 3.3% 4.4% 7.3% 10.0%
Symptomatic 10.9% 10.3% 12.8% 16.0%
P.P.V. for All subjects 5.3% 4.9% 5.3% 3.8%
cancer Asymptomatic 9.5% 7.7% 7.9% 5.2%
Symptomatic 0 0 0 0
P.P.V. for All subjects 18.4% 21.9% 12.3% 12.7%
adenomas Asymptomatic 19.0% 19.2% 13.2% 10.3%
Symptomatic 17.6% 26.7% 10.5% 19.0%
Specificity All subjects (*) 96.1% 96.0% 93.8% 91.2%
for cancer Asymptomatic (**) 97.5% 96.9% 95.0% 91.9%
and adenomas Symptomatic (***) 90.5% 91.8% 88.4% 88.4%
(*) Significant differences: R. Ho vs Hemodia P<0.05; R. Ho vs Hemesel
P<0.001; Ho S. vs Hemodia P<0.05; Ho S. vs Hemesel P<0.001; Hemodia vs
Hemesel P<0.05. (**) Significant differences: R. Ho vsHemodia P<0.05; R. Ho
vs Hemesel P<0.001; Ho S vs Hemesel P<0.001; Hemodia vs Hemesel P<0.05;
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tomatic n = 29, Symptomatic n = 12) and 6.5% (n = 51;
Asymptomatic n = 34, Symptomatic n = 17) respectively.
Table III shows the positivity and specificity rates and the
P.P.V. for cancer and adenomas ofeach test on 1-day testing.
Positivity rates are lower and P.P.V. and specificity rates are
higher compared to 3-day testing for all studied tests.
Differences between tests are almost the same as observed at
3-day testing.
The specificity of guaiac tests at 3-day testing (Table II)
and the one of immunochemical tests at 1-day testing in
corresponding subgroups (Table III) does not differ
significantly.
Discussion
In the present study we have used rehydrated Hemoccult as a
standard reference, although some authors consider that the
reduction of specificity for cancer and adenomas from 98%
to 94% induced by rehydration makes Hemoccult too un-
specific for screening purposes. In our opinion, this reduction
in specificity can be justified by the relevant increase in
sensitivity obtained when rehydration is introduced (Ke-
wenter et al., 1988). In fact specificity is an important deter-
minant of screening feasibility, but a satisfactory sensitivity is
also needed for screening efficacy. The results of the present
study show that immunochemical tests specificity and P.P.V.
are lower compared to guaiac ones and, in our opinion, the
use of 3-day immunochemical testing in a screening setting is
not recommended due to the excess of false positive results.
Nevertheless, the specificity of immunochemical tests at
1-day testing is comparable to the one of guaiac tests at
3-day testing.
One-day immunochemical testing would certainly improve
screening acceptability as it would reduce the period of faecal
sample collection and no restrictive diet would be required.
One possible adverse effect of 1-day compared to 3-day
testing might be a drop in sensitivity. The low number of
lesions detected in the present study, particularly in the group
of symptomatic subjects, doesn't allow for sensitivity
estimates, but it should be noted that the drop in colorectal
neoplasms (cancer or adenomas) detection rate observed for
guaiac tests and Hdia at 1-day compared to 3-day testing
(R.HO: 5/18 vs 9/18; HOS: 7/18 vs 11/18; Hdia: 6/18 vs
10/18) is less evident for Hsel (10/18 vs 13/18) and the
detection rate of Hsel at 1-day testing is comparable to that
of other tests at 3-day testing.
These findings suggest that 1-day immunochemical testing
with Hsel might be an alternative to classic 3-day guaiac
testing. The detection rate of colonic neoplasms is not
reduced and screening acceptability would be certainly in-
creased as faecal sample collection is simpler and no diet is
required.
Of course, these preliminary observations need to be
confirmed in a screening situation with a proper study design
and a larger series, allowing for a more reliable estimate of
sensitivity.
Table III Positivity rates, P.P.V. for cancer and adenomas, and specificity
estimates at 1-day testing for each test according to symptomatic status
R.HO HO.S HDIA HSEL
Positivity All subjects 2.4% 2.8% 5.2% 6.5%
rates Asymptomatic 1.4% 1.7% 4.6% 5.4%
Symptomatic 6.4% 7.0% 7.0% 10.9%
P.P.V. for All subjects 10.5% 9.5% 5.7% 6.2%
cancer Asymptomatic 22.2% 20.0% 8.7% 9.1%
Symptomatic 0 0 0 0
P.P.V. for All subjects 15.8% 28.6% 11.4% 14.6%
adenomas Asymptomatic 11.1% 30.0% 13.0% 15.1%
Symptomatic 20.0% 27.3% 8.3% 13.3%
Specificity All subjects (*) 98.1% 98.3% 96.1% 94.9%
for cancer Asymptomatic (**) 99.0% 99.2% 97.0% 95.9%
and adenomas Symptomatic (***) 94.5% 94.6% 92.5% 91.2%
(*) Significant differences: R. Ho vs Hemodia P<0.01; R. Ho vs Hemesel
P<0.001; HoS. vs Hemodia P<0.01; HoS. vs Hemesel P<0.001. (**)
Significant differences: R. Ho vs Hemodia P<0.01; R. Ho vs Hemesel P<0.001;
Ho S vs Hemodia P<0.01; Ho S vs Hemesel P<0.001. (***) Significant
differences: None.
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